Dr. Curran frames the discussion around the Freyer et al. finding that AYA patients with ALL treated with non-PIRs are significantly more likely to undergo allogeneic stem cell transplant (allo-SCT) in first remission (33% versus 16% at 2 years), with associated higher patient burden and greater healthcare resource utilization.
Dr. Silverman discusses the evolution of premedication practice for pegaspargase in AYA ALL, noting that the CALGB 10403 trial incorporated a protocol amendment requiring premedication after hypersensitivity events became frequent during accrual.
Dr. Silverman opens a discussion on dose capping and empiric dose reduction of pegaspargase (PEGylated asparaginase) in the adult and AYA setting.
Dr. Silverman introduces the Haematologica expert consensus published by Dr. Curran and colleagues in December 2025, describing it as the most comprehensive adult-focused guidance available on recognizing and managing asparaginase-associated adverse events.
Dr. Silverman discusses the 2026 ASH guidelines for frontline management of ALL in AYAs, asking Dr. Curran to walk through the headline recommendations and practical takeaways for adult oncologists adopting pediatric-inspired regimens.
Dr. Silverman asks Dr. Curran to address how frontline therapy goals have evolved for young adults with ALL in the era of pediatric-inspired regimens (PIRs). Dr. Curran describes a significant paradigm shift: the historical standard in adult oncology held that young, fit patients should achieve remission as a bridge to allogeneic stem cell transplant (allo-SCT), which was considered to offer the best chance of long-term cure. Data supporting PIRs in AYA ALL have fundamentally changed this calculus.
Dr. Lewis Silverman introduces the program on pediatric-inspired asparaginase-based regimens in adolescent and young adult (AYA) ALL, joined by Dr. Emily Curran. The discussion focuses on the 2026 real-world analysis by Freyer and colleagues, which demonstrated significantly higher overall survival in AYAs with ALL treated with guideline-concordant pediatric-inspired regimens compared to adult-inspired regimens. Dr. Curran notes that no randomized trial comparing pediatric-inspired versus adult regimens in the AYA population has been completed to date; the accumulating retrospective and prospective data nonetheless strongly favor pediatric-inspired regimens over historical adult controls.
